View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Lifecore Biomedical Reports Financial Results for the Three Months End...

Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update -- Recorded $31.1 Million in Revenue During the Three Months Ended September 30, 2025, Representing a 26% Increase From Comparable Period of 2024 -- -- Multiple New Programs Signed with New Customers -- -- Continued Improvements in Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development an...

Antoine Legault ... (+2)
  • Antoine Legault
  • Matthew Bryson

Daily Views on Tech Headlines

Tariffs, Tech, NATL: Reciprocal tariffs in Jeopardy?View: The Supereme Court justices appeared skeptical of the Trump administration's arguments that the Executive Branch has the power to levy broad reciprocal tariffs. While we would see a return to a pre-reciprocal tariff regimen as broadly positi

Dan Salmon
  • Dan Salmon

Meta Platforms (META, Buy, $800 target) AI investment = Metaverse inve...

Our target declines to $800 from $900 on lower estimates. With that said, 4Q25 revenue guidance appears low, with both implied impression and pricing growth decelerating against easier comps. In the report, we also discuss the AI = Metaverse narrative that has taken hold, the addition of $30B of new debt and why we are ending share buybacks in our model.

 PRESS RELEASE

Lifecore Biomedical to Report Financial Results for the Three Months E...

Lifecore Biomedical to Report Financial Results for the Three Months Ended September 30, 2025, on November 6, 2025 Webcast Scheduled for Thursday, November 6 at 4:30 p.m. Eastern CHASKA, Minn., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the three months ended September 30, 2025, on Thursday, November 6, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team ...

Pierre FerraguÊ
  • Pierre FerraguÊ

2026 AI Infra. outlook forming: XPU spending catching up with capex, u...

It has been a busy week with Nvidia’s comments in Washington and three hyperscalers reporting last night. Building on these updates, we have already formed a very insightful perspective on how AI infrastructure deployments are shaping up for next year. Please follow the link for our insight summarized on a single slide.

Moody's Ratings assigns Aa3 rating to Meta's new senior unsecured note...

Moody's Ratings (Moody's) assigned Aa3 ratings to Meta Platforms, Inc.'s (Meta) proposed senior unsecured notes, which will be comprised of various maturities. Meta will use the proceeds from the proposed offering for general corporate purposes. The outlook remains unchanged at stable. RATINGS RAT...

Antoine Legault ... (+2)
  • Antoine Legault
  • Matthew Bryson

Daily Views on Tech Headlines

Shipments in Q4 are expected to dip 10% Q/Q given reduced inventories to pull from and Samsung's ongoing conversion of older lines (which is weighing on output).Capex: The company is considering a significant increase in capex in 2026. DRAM - Management noted spend should skew towards DRAM. For DRA

Chase Tohanczyn ... (+4)
  • Chase Tohanczyn
  • Daniel Ives
  • Matthew Weiss
  • Scott Devitt

Investment Cycle Continues; OP, $920 PT

Figure 1. 3Q25 ResultsSource: Company reports, Wedbush estimates, FactSet consensusNote: 3Q revenue guide in the range of $42.5-$45.5B.Meta delivered strong 3Q results. Revenue in the quarter reached $51.2B (+26.2% Y/Y), ahead of consensus of $49.5B (+21.9% Y/Y) by ~4%. Revenue was well above the h

Dan Salmon
  • Dan Salmon

Meta Platforms (META, Buy, $900 target) Inline revenue outlook but AI ...

What’s New: In this first take following tonight’s results, we focus on: 1. Weakness driven by inline revenue outlook and ominous AI investment language 2. No big surprises in ad revenue, but short of the most bullish buyside expectations 3. Capex fears confirmed, but the door was also opened to a potential neo cloud business 4. First comments on 2026 expense growth spook

 PRESS RELEASE

Lifecore Biomedical Selected as New Commercial Manufacturing Partner b...

Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company Lifecore to Execute Commercial Site Transfer and Become New Supplier of Choice for Leading Commercial Injectable Pharmaceutical Product Represents Second Agreement Signed with Same Major Multinational Organization in Recent Months Separate Pre-Clinical Formulation Development Agreement Signed with New Early-Stage Biotech Customer CHASKA, Minn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manuf...

Antoine Legault ... (+2)
  • Antoine Legault
  • Matthew Bryson

Daily Views on Tech Headlines

DRAM demand growth: Forecast to rise from high-teens % in 2025 to 20%+ in 2026. Hynix is emphasizing its transition to 1C to support conventional DRAM demand (expected to represent >50% of Korean capacity by end of 2026) and its ramp of M15X to increase HBM output in 2026.NAND demand/supply grow

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch